JW Therapeutics maintains that its operations and partnership discussions have proceeded without interruption, despite Beijing stepping up scrutiny of technology-related foreign deals, the company’s CEO said on Tuesday.
Leo Tian, chief executive of JW Therapeutics, told Reuters that the firm has seen no practical impact so far from the Chinese authorities' more exacting review of overseas transactions. "For us, everything is business as usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly dependent on international cooperation. So far, I have not seen any impact," he said.
The comments come amid broader market movements: international pharmaceutical companies are reportedly accelerating their efforts to license experimental drugs developed in China as they look to rein in costs ahead of looming patent expirations. Industry analysts cited in the reporting expect biotech licensing agreements to set a new high this year.
Concerns about a tighter regulatory environment for tech-linked deals intensified last month when China ordered U.S. social media company Meta to reverse its acquisition of artificial intelligence start-up Manus, a deal valued at more than $2 billion. That decision is being interpreted as part of a tougher stance on U.S. investment in Chinese firms working on advanced technologies and has introduced an element of uncertainty across multiple sectors.
JW Therapeutics, which develops cell immunotherapy products, counts U.S. drugmaker Bristol Myers Squibb as its largest shareholder via BMS’s wholly owned unit Juno Therapeutics. Tian said JW is actively exploring collaborations with partners outside China to advance assets in its development pipeline.
Observers have suggested that the blocking of Meta’s Manus deal could raise the perceived risk for international investors targeting advanced technology companies with ties to China, though Tian’s remarks indicate JW Therapeutics has not experienced direct repercussions to its cross-border clinical and development work.
Context and implications
- Global pharma firms are increasingly looking to China-origin experimental treatments as part of cost management and pipeline replenishment strategies.
- Heightened regulatory scrutiny of technology transactions has created uncertainty beyond the tech sector, affecting investor sentiment in adjacent industries.
- JW Therapeutics reports uninterrupted cross-border collaboration in the CGT space despite the regulatory environment.